Literature DB >> 32144493

Spot urinary sodium in acute decompensation of advanced heart failure and dilutional hyponatremia: insights from DRAIN trial.

Alessandro Galluzzo1, Simone Frea2, Paolo Boretto2, Stefano Pidello2, Alessandra Volpe2, Federico Giovanni Canavosio3, Pier Giorgio Golzio2, Serena Bergerone2, Gaetano Maria De Ferrari2.   

Abstract

BACKGROUND: Diuretic resistance portends a poor prognosis in acute heart failure, especially in advanced stages. Early identification of a poor response to diuretics may help to improve treatment and outcomes. Spot natriuresis (UNa+) at 2 h from the start of intravenous furosemide has been proposed as an early indicator of diuretic response. Our paper aimed to determine the role of early natriuresis in patients hospitalized with advanced chronic heart failure (ACHF) and high risk of diuretic resistance. METHODS AND
RESULTS: We performed a sub-analysis of the DRAIN trial, a randomized clinical trial on 80 patients with acute decompensation of ACHF (NYHA IV, EF ≤ 30%) with low systolic blood pressure (≤ 110 mmHg) and dilutional hyponatremia (sodium ≤ 135 mMol/L) at admission. Patients were divided into two groups according to spot urinary sodium excretion (high: UNa+  > 50 or low: ≤ 50 mEq/L) at 2 h from furosemide administration. Twenty-eight patients (35%) showed a low natriuretic response. As compared to the other patients, this group showed lower daily urinary output (2275 ± 790 vs 3849 ± 2034 mL, p < 0.001), lower body weight reduction after 48 h (1.55 ± - 1.66 vs - 3.55 ± - 2.93 kg, p < 0.001), higher incidence of worsening renal function (32% vs 10%, p 0.02) and increasing rather than reducing NT-proBNP at 72 h (p 0.02).
CONCLUSIONS: In patients with ACHF and dilutional hyponatremia, low natriuresis after furosemide is an early marker of poor diuretic response and correlates with higher NT-proBNP and higher incidence of worsening renal function at 72 h.

Entities:  

Keywords:  Acute heart failure; Advanced heart failure; Diuretic resistance; Hyponatremia; Natriuretic peptides

Mesh:

Substances:

Year:  2020        PMID: 32144493     DOI: 10.1007/s00392-020-01617-w

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  4 in total

1.  Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study.

Authors:  Jeroen Dauw; Malgorzata Lelonek; Isabel Zegri-Reiriz; Cynthia P Paredes-Paucar; Cornelia Zara; Varghese George; Marta Cobo-Marcos; Dorit Knappe; Dmitry Shchekochikhin; Annop Lekhakul; Milka Klincheva; Simone Frea; Òscar Miró; Diane Barker; Attila Borbély; Samer Nasr; Nawal Doghmi; Rafael de la Espriella; Jagdeep S Singh; Virginia Bovolo; Inês Fialho; Noel T Ross; Mieke van den Heuvel; Riad Benkouar; Hajo Findeisen; Imad A Alhaddad; Kais Al Balbissi; Gonzalo Barge-Caballero; Azmee M Ghazi; Liesbeth Bruckers; Pieter Martens; Wilfried Mullens
Journal:  ESC Heart Fail       Date:  2021-10-28

2.  Renoprotection by long-term low-dose tolvaptan in patients with heart failure and hyponatremia.

Authors:  Tatsufumi Oka; Takayuki Hamano; Tomohito Ohtani; Yohei Doi; Karin Shimada; Ayumi Matsumoto; Satoshi Yamaguchi; Nobuhiro Hashimoto; Masamitsu Senda; Yusuke Sakaguchi; Isao Matsui; Kei Nakamoto; Fusako Sera; Shungo Hikoso; Yasushi Sakata; Yoshitaka Isaka
Journal:  ESC Heart Fail       Date:  2021-09-23

3.  Urine biochemistry assessment in the sequential evaluation of renal function: Time to think outside the box.

Authors:  Alexandre T Maciel; Daniel Vitorio; Eduardo A Osawa
Journal:  Front Med (Lausanne)       Date:  2022-07-26

4.  Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? Reply.

Authors:  Kevin Damman; Jozine M Ter Maaten; Peter van der Meer
Journal:  Eur J Heart Fail       Date:  2020-04-16       Impact factor: 15.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.